Clinical Trials Browser

Phase 2/3 × Active not recruiting × camrelizumab × Clear all

NCT04208347 2026-01-23

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Phase 2/3 Active not recruiting

Adenocarcinoma

NCT04521153 2025-05-11

Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma

Phase 2/3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular